The latest from BioStock
» BioStock Investor Pitch: Brain+
» Biosergen on track for first patient study with antifungal treatment
» Alzinova's CEO on the Alzheimer's vaccine of the future
» Redemption in Moberg's TO 2 funds international Terclara launch
» Elicera Therapeutics CEO talks about the future of immunotherapy
Read BioStock's weekly newsletter for v.23 here.
BioStock Global Forum
The two-day event took place last week. See all presentations and panel discussions here.
The latest news of the day
Ultimovacs provides update from phase I study in malignant melanoma: continued strong survival in patients treated with UV1 cancer vaccine and pembrolizumab. Read more.
Elicera Therapeutics preclinical collaboration agreement is entered into with China Medical University for the development of ELC-201. Read more.
Phase Holographic includes collaboration with University College London to use HoloMonitor in a research project. Read more.
Bone support announces that an Australian study shows that CERAMENT contributes to fewer amputations. Read more.
CS Medica plans to spin off the subsidiary CANNORDIC and listing on the German stock market. Read more.
CLS publishes a prospectus in connection with an upcoming rights issue. Read more.
AegirBio receives additional milestone payments during RadX NIH Program. Read more.
Nykode Therapeutics announces that mRNA-LNP cancer vaccine shows good efficacy. Read more.
Cantargia strengthens the management team through the recruitment of Ton Berkien as Chief Business Officer. Read more.
Brain+ announces that the subscription period in the rights issue begins today. Read more.
The news channel Sky News focuses on PolarCool and interviews the CEO Erik Anderson. Read more.
Integral enters into a cooperation and distribution agreement with Hanger which is a leading American company in amputation. Read more.
Moberg Pharma has secured the use of warrants and entered into a free top guarantee. Read more.
PMDS intends to carry out a rights issue of approximately SEK 27,5 million and provides a market update regarding the business model. Read more.
Nanexa announces that the first patient has been dosed in the phase I study with NEX-22 in type 2 diabetes. Read more.
Vimian enters into a settlement agreement with one of the main sellers of VOI in the previously communicated damages process related to the US patent dispute. Read more.
Qlife Holding has ongoing negotiations with Atlas Special Opportunities regarding financing solution. Read more.
Cyxone appoints Henrik Hang to interim CFO. Read more.
Alvotech and WHAT TO expands its strategic partnership through collaboration on denosumab. Read more.
Scandinavian ChemoTech sees a significant increase in repeat purchases of its vetIQure TSE system. Read more.
Peptonic Medical provides an operational update after the first 120 days with a new CEO. Read more.
Communiqué and meetings
This morning's price development
Index: OMXS30 +0,09% Healthcare -0,13%
| Winner | Förlorare |
| Medfield 33,53% | Ecti Research -24,5% |
| Ultimovacs 25% | 2cureX -20% |
| Bio-Works 17,65% | Lipids -20% |
| Moberg Pharma 14,5% | CS Medica -17,09% |
| Lumito 15,27% | Perpetua Medical -14,74% |